Grantham Mayo Van Otterloo & Co. LLC Buys 42,491 Shares of Sanofi $SNY

Grantham Mayo Van Otterloo & Co. LLC raised its stake in shares of Sanofi (NASDAQ:SNY) by 99.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 85,164 shares of the company’s stock after acquiring an additional 42,491 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Sanofi were worth $4,020,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Caprock Group LLC bought a new position in shares of Sanofi during the 3rd quarter valued at approximately $1,347,000. Assetmark Inc. raised its holdings in shares of Sanofi by 25.0% in the 3rd quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock worth $16,859,000 after purchasing an additional 71,356 shares during the period. Thrivent Financial for Lutherans raised its holdings in shares of Sanofi by 10,152.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock worth $103,846,000 after purchasing an additional 2,178,647 shares during the period. NewEdge Wealth LLC lifted its stake in Sanofi by 63.1% in the third quarter. NewEdge Wealth LLC now owns 67,303 shares of the company’s stock valued at $3,298,000 after purchasing an additional 26,035 shares during the last quarter. Finally, Willis Investment Counsel lifted its stake in Sanofi by 11.3% in the third quarter. Willis Investment Counsel now owns 556,700 shares of the company’s stock valued at $26,276,000 after purchasing an additional 56,500 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Sanofi stock opened at $44.35 on Tuesday. Sanofi has a 1-year low of $43.34 and a 1-year high of $60.12. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $108.17 billion, a PE ratio of 12.32, a price-to-earnings-growth ratio of 1.15 and a beta of 0.45. The firm’s 50 day simple moving average is $47.23 and its 200 day simple moving average is $48.40.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SNY. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Guggenheim lowered Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Barclays cut Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. Finally, Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. Five equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Hold” and a consensus target price of $62.67.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.